JP2018504419A5 - - Google Patents

Download PDF

Info

Publication number
JP2018504419A5
JP2018504419A5 JP2017540316A JP2017540316A JP2018504419A5 JP 2018504419 A5 JP2018504419 A5 JP 2018504419A5 JP 2017540316 A JP2017540316 A JP 2017540316A JP 2017540316 A JP2017540316 A JP 2017540316A JP 2018504419 A5 JP2018504419 A5 JP 2018504419A5
Authority
JP
Japan
Prior art keywords
seq
motif
sequence
amino acids
cst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017540316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504419A (ja
JP6655626B2 (ja
Filing date
Publication date
Priority claimed from GBGB1418433.7A external-priority patent/GB201418433D0/en
Application filed filed Critical
Publication of JP2018504419A publication Critical patent/JP2018504419A/ja
Publication of JP2018504419A5 publication Critical patent/JP2018504419A5/ja
Application granted granted Critical
Publication of JP6655626B2 publication Critical patent/JP6655626B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017540316A 2014-10-17 2015-10-16 新規な免疫原性ペプチド Active JP6655626B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1418433.7 2014-10-17
GBGB1418433.7A GB201418433D0 (en) 2014-10-17 2014-10-17 Novel immunogenic peptides
PCT/EP2015/074063 WO2016059236A1 (en) 2014-10-17 2015-10-16 Novel immunogenic peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020016331A Division JP2020079271A (ja) 2014-10-17 2020-02-03 新規な免疫原性ペプチド

Publications (3)

Publication Number Publication Date
JP2018504419A JP2018504419A (ja) 2018-02-15
JP2018504419A5 true JP2018504419A5 (https=) 2018-11-22
JP6655626B2 JP6655626B2 (ja) 2020-02-26

Family

ID=52013133

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017540316A Active JP6655626B2 (ja) 2014-10-17 2015-10-16 新規な免疫原性ペプチド
JP2020016331A Pending JP2020079271A (ja) 2014-10-17 2020-02-03 新規な免疫原性ペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020016331A Pending JP2020079271A (ja) 2014-10-17 2020-02-03 新規な免疫原性ペプチド

Country Status (16)

Country Link
US (3) US20180228912A1 (https=)
EP (2) EP3207053B1 (https=)
JP (2) JP6655626B2 (https=)
KR (1) KR102556485B1 (https=)
CN (1) CN107148427B (https=)
AU (2) AU2015332621B2 (https=)
BR (1) BR112017007773A2 (https=)
CA (1) CA2964426C (https=)
DK (1) DK3207053T3 (https=)
ES (1) ES2751605T3 (https=)
GB (1) GB201418433D0 (https=)
MX (1) MX374635B (https=)
PL (1) PL3207053T3 (https=)
PT (1) PT3207053T (https=)
RU (1) RU2709711C2 (https=)
WO (1) WO2016059236A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
EP2626081B1 (en) 2008-02-14 2017-03-22 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
ES2637812T3 (es) 2008-02-14 2017-10-17 Life Sciences Research Partners Vzw Inmunoterapia dirigida a patógenos intracelulares
DE11787873T1 (de) 2010-11-25 2013-12-12 Imnate Sarl Immugene Peptide zur Verwendung bei der Vorbeugung und/oder Behandlung von Infektionskrankheiten, Autoimmunerkrankungen, Immunreaktionen auf Allofaktoren, allergischen Erkrankungen, Tumoren, Transplantatabstossungen und Immunreaktionen auf virale Vektoren
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
WO2019113342A1 (en) 2017-12-07 2019-06-13 Sanford Burnham Prebys Medical Discovery Institute Compositions and methods for treating nervous system injuries
WO2017040976A1 (en) * 2015-09-02 2017-03-09 Erkki Ruoslahti Compounds and compositions for targeting brain injuries and methods of use thereof
CA2995771A1 (en) 2015-09-25 2017-03-30 Imcyse Sa Improved methods and compounds for eliminating immune responses to therapeutic agents
BR112018071466A2 (pt) * 2016-04-19 2019-03-19 Imcyse Sa novos peptídeos de ligação a cd1d imunogênicos
JP7102430B2 (ja) * 2017-03-09 2022-07-19 アンシス・エスア 糖尿病の治療のためのペプチド及び方法
US20210401976A1 (en) 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
CN113906046A (zh) 2019-05-16 2022-01-07 易姆赛斯股份公司 具有包含经修饰半胱氨酸的氧化还原酶基序的免疫原性肽
WO2021105371A1 (en) 2019-11-27 2021-06-03 Imcyse Sa Methods for stratifying diabetes patients
CA3182369A1 (en) * 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
EP4146255A1 (en) 2020-05-06 2023-03-15 Imcyse SA Immunogenic peptides with new oxidoreductase motifs
US20240189404A1 (en) * 2020-05-06 2024-06-13 Imcyse Sa Immunogenic peptides with extended oxidoreductase motifs
AR122023A1 (es) 2020-05-06 2022-08-03 Imcyse Sa Péptidos y métodos para el tratamiento de esclerosis múltiple
EP3915575A1 (en) * 2020-05-29 2021-12-01 Imnate Sarl Vaccine formulations
EP4321528A4 (en) * 2021-04-09 2025-04-30 Ajou University Industry-Academic Cooperation Foundation PEPTIDE FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES
CN117750971A (zh) 2021-05-26 2024-03-22 易姆赛斯股份公司 治疗或预防自身免疫病的方法
JP2024520952A (ja) 2021-06-01 2024-05-27 アンシス・エスア 免疫原性ペプチドを使用した改善された処置方法
WO2022256637A2 (en) * 2021-06-03 2022-12-08 David Weiner Synthetic dna vaccine immunogenic improvements
AR126654A1 (es) 2021-06-29 2023-11-01 Imcyse Sa Péptidos y métodos para el tratamiento de neuromielitis óptica

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4886782A (en) 1987-02-26 1989-12-12 The United States Of America As Represented By The Department Of Health And Human Services Malarial immunogen
US5433948A (en) 1990-02-13 1995-07-18 Thomas; Wayne R. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
FI931393A0 (fi) 1990-09-27 1993-03-26 Syntello Vaccine Dev Kb Peptider foer anvaendning vid vaccinering och induktion av neutraliserande motkroppar mot humant immunbristvirus
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5589582A (en) 1992-10-27 1996-12-31 Biotransplant, Inc. Polynucleotides en coding porcine cytokines
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
DE69435171D1 (de) 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US6399383B1 (en) 1997-10-28 2002-06-04 Maxygen, Inc. Human papilloma virus vectors
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
AR020102A1 (es) 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
US20030152581A1 (en) 1998-07-30 2003-08-14 Jean-Marie Saint-Remy Compound and method for the prevention and/or the treatment of allergy
US6656471B1 (en) 1998-11-17 2003-12-02 Board Of Regents, The University Of Texas System HIV-specific T-cell induction
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
WO2001055393A2 (en) 2000-01-28 2001-08-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
GB0006437D0 (en) 2000-03-17 2000-05-10 Leuven Res & Dev Vzw Compounds for the modulation of allergen sensitivity by antigens sharing T cell epitopes with allergens
EP1294905A1 (en) 2000-06-26 2003-03-26 SmithKline Beecham Biologics SA Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
JP2004527263A (ja) 2001-05-30 2004-09-09 フォンダツィオーネ テレソン 免疫抑制活性を有するエクスビボ単離cd25+cd4+t細胞とその使用
DE60231417D1 (de) 2001-10-03 2009-04-16 Unilever Nv Kohlenhydratbindungsdomäne enthaltende fusionsproteine zur verabreichung von therapeutischen und anderen stoffen und zusammensetzungen in denen die fusionsproteine enthalten sind
US20100183652A1 (en) 2002-02-21 2010-07-22 Mark Page STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
WO2003072731A2 (en) 2002-02-21 2003-09-04 Apovia, Inc. STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
DE60327786D1 (de) 2002-09-12 2009-07-09 Oncotherapy Science Inc Kdr-peptide und diese enthaltende impfstoffe
US20070054262A1 (en) 2003-03-28 2007-03-08 Baker Denise M Methods of identifying optimal variants of peptide epitopes
US7651855B2 (en) 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
CA2537900A1 (en) 2003-09-03 2005-04-28 Dendritherapeutics, Inc. Multiplex vaccines
GB0324265D0 (en) 2003-10-16 2003-11-19 Medical Res Council Peptide
US20070184023A1 (en) 2003-10-30 2007-08-09 Pharmexa A/S Method for down-regulation of vegf
CA2571168A1 (en) 2004-06-17 2006-01-26 Mannkind Corporation Mhc i-binding ssx-241-49 variants
US8252893B2 (en) 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
WO2007027954A2 (en) 2005-08-30 2007-03-08 Children's Hospital & Research Center At Oakland Methods for identifying an epitope of a polypeptide, chlamydial antigenic polypeptides identified thereby, and methods of use thereof
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
GB0603081D0 (en) 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
WO2007135684A2 (en) 2006-05-22 2007-11-29 Hadasit Medical Research Services & Development Limited Method of treatment of anti-cd4 autoimmunity
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
ES2602610T3 (es) 2007-05-31 2017-02-21 Medigene Ag Proteína estructural mutada de un parvovirus
CA2700618A1 (en) 2007-09-27 2009-04-02 The Board Of Trustees Of The University Of Arkansas Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor
EP2050814A1 (en) * 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
EP2252329B1 (en) 2008-02-14 2015-06-17 Life Sciences Research Partners VZW Elimination of immune responses to viral vectors
ES2584430T3 (es) 2008-02-14 2016-09-27 Life Sciences Research Partners Vzw Estrategias para prevenir y/o tratar las respuestas inmunitarias a los alofactores solubles
US9248171B2 (en) 2008-02-14 2016-02-02 Imcyse Sa Immunogenic peptides and their use in transplantation
EP2626081B1 (en) 2008-02-14 2017-03-22 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
ES2637812T3 (es) 2008-02-14 2017-10-17 Life Sciences Research Partners Vzw Inmunoterapia dirigida a patógenos intracelulares
EP2245059B1 (en) 2008-02-14 2017-09-20 Life Sciences Research Partners VZW Cd4+ t-cells with cytolytic properties
EP2254592B1 (en) 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
KR101022649B1 (ko) 2008-08-07 2011-03-22 삼성모바일디스플레이주식회사 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치
AU2010232512B2 (en) 2009-04-01 2013-07-18 University Of Miami Vaccine compositions and methods of use thereof
EP3156068B1 (en) 2010-03-29 2021-11-03 CNRS (Centre National de la Recherche Scientifique) Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof
WO2013121296A1 (en) 2012-02-15 2013-08-22 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
DE11787873T1 (de) 2010-11-25 2013-12-12 Imnate Sarl Immugene Peptide zur Verwendung bei der Vorbeugung und/oder Behandlung von Infektionskrankheiten, Autoimmunerkrankungen, Immunreaktionen auf Allofaktoren, allergischen Erkrankungen, Tumoren, Transplantatabstossungen und Immunreaktionen auf virale Vektoren
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
JP2015518376A (ja) * 2012-04-30 2015-07-02 イムシス・ソシエテ・アノニムImcyse Sa 抗原特異的な調節性t細胞を誘導するための方法
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201319160D0 (en) 2013-10-30 2013-12-11 Imcyse Sa Methods for induction of antigen-specific regulatory t cells
AU2014343379B2 (en) 2013-11-04 2019-02-14 Uti Limited Partnership Methods and compositions for sustained immunotherapy
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
CA2995771A1 (en) 2015-09-25 2017-03-30 Imcyse Sa Improved methods and compounds for eliminating immune responses to therapeutic agents
BR112018071466A2 (pt) 2016-04-19 2019-03-19 Imcyse Sa novos peptídeos de ligação a cd1d imunogênicos
JP7102430B2 (ja) 2017-03-09 2022-07-19 アンシス・エスア 糖尿病の治療のためのペプチド及び方法
US20210401976A1 (en) 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
CN113906046A (zh) 2019-05-16 2022-01-07 易姆赛斯股份公司 具有包含经修饰半胱氨酸的氧化还原酶基序的免疫原性肽

Similar Documents

Publication Publication Date Title
JP2018504419A5 (https=)
RU2017111657A (ru) Новые иммуногенные пептиды
RU2018136760A (ru) НОВЫЕ ИММУНОГЕННЫЕ CD1d-СВЯЗЫВАЮЩИЕ ПЕПТИДЫ
AR122964A2 (es) Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
WO2018191502A3 (en) Anti-cd137 antibodies and methods of use thereof
CL2019003427A1 (es) Nuevos péptidos (seq id n°180), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
FI3430027T3 (fi) Peptidi käytettäväksi ei-pienisoluisen keuhkosyövän ja pienisoluisen keuhkosyövän hoidossa
PE20240645A1 (es) Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores
EA202191027A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей
JP2019514895A5 (https=)
NZ618391A (en) Antigenic tau peptides and uses thereof
MX2024014422A (es) Metodos para predecir la utilidad de modificaciones de aminoacidos especificas de una enfermedad para inmunoterapia
UA103751C2 (ru) Иммуногенный пептид для иммунотерапии
PE20190355A1 (es) Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo
RU2019126232A (ru) Пептиды и способы для лечения диабета
MX377692B (es) Peptidos anti-inflamatorios y usos de los mismos.
EP4411376A3 (en) Methods for predicting the usefulness of neoantigens for immunotherapy
MX387764B (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
CL2019003328A1 (es) Nuevos epítopos celulares y nuevas combinaciones de epítopos celulares para el uso en la inmunoterapia del mieloma y de otros tipos de cáncer. (divisional solicitud 201703244)
NZ596501A (en) Casb7439 constructs
CR20200632A (es) Péptidos restringidos por a*03 par el uso en la inmunoterapia contra el cáncer y métodos relacionados
ZA202100761B (en) Improvements in immunogenic conjugates
PH12023553212A1 (en) Improved methods of treatment using immunogenic peptides
JP2005524719A5 (https=)
RU2011120447A (ru) Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины